Welcome to our dedicated page for Instil Bio news (Ticker: TIL), a resource for investors and traders seeking the latest updates and insights on Instil Bio stock.
Instil Bio, Inc. reports developments as a Nasdaq-listed biopharmaceutical company focused on identifying and advancing innovative therapeutic opportunities. Company updates have covered financial results, capital resources, restructuring and impairment charges, strategic development efforts, licensing activity, and subsidiary actions through Axion Bio.
Recent announcements also document the completed discontinuation of clinical development of AXN-2510 and the termination of related license and collaboration rights, after earlier updates on the PD-L1xVEGF bispecific antibody program, FDA IND clearance, non-small cell lung cancer data presented by ImmuneOnco, and solid-tumor development activity.
Instil Bio, Inc. reported its first quarter 2024 financial results, showcasing a cash balance of $161.5 million, expected to fund operations beyond 2026. The company highlighted successful feasibility studies, plans for a potential trial in non-small cell lung cancer, and exploring new therapeutic candidates. Research and development expenses decreased, while general and administrative expenses remained stable. Non-GAAP net loss per share improved from the previous year.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Instil Bio (NASDAQ: TIL) has confirmed a cash runway extending beyond 2026, following a consolidation of R&D operations in Manchester, UK. The company anticipates initiating its ITIL-306 phase 1 study in the second half of 2023, pending Clinical Trial Application clearance from the UK MHRA, and expects initial clinical data in 2024. For Q4 2022, Instil reported a net loss of $53.8 million, with total cash and equivalents of $260.9 million as of December 31, 2022. Research and development expenses decreased to $20.7 million from $42.6 million in Q4 2021, while general and administrative expenses increased to $12.9 million compared to $11.2 million in the same quarter last year.